Published in J Ethnopharmacol on December 14, 2008
In vivo toxicity evaluation of a standardized extract of Syzygium aqueum leaf. Toxicol Rep (2014) 0.78
Medicinal plants used for management of malaria among the Luhya community of Kakamega East sub-County, Kenya. J Ethnopharmacol (2016) 0.75
Comparison of Ultrasound-assisted Extraction and Dynamic Maceration Over Content of Tagitinin C obtained from Tithonia diversifolia (Hemsl.) A. Gray Leaves Using Factorial Design. Pharmacogn Mag (2017) 0.75
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
mTOR and cancer therapy. Oncogene (2006) 3.07
alpha-Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to Phyllanthus amarus. J Ethnopharmacol (2006) 2.38
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ (1990) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation. J Biol Chem (1999) 2.08
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer (2004) 1.92
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res (1999) 1.89
Amplification of the gli gene in childhood sarcomas. Cancer Res (1989) 1.84
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst (1998) 1.82
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet (1987) 1.60
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res (2001) 1.56
Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol (1994) 1.55
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res (1999) 1.47
Monoclonal antibodies to the myogenic regulatory protein MyoD1: epitope mapping and diagnostic utility. Cancer Res (1992) 1.43
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol (1999) 1.41
Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol (1998) 1.41
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res (2000) 1.35
Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol (1990) 1.34
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Anti-inflammatory activities of the methanol extracts and an isolated furanoditerpene constituent of Sphenocentrum jollyanum Pierre (Menispermaceae). J Ethnopharmacol (2005) 1.29
Mechanisms of resistance to rapamycins. Drug Resist Updat (2001) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res (2001) 1.26
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1997) 1.25
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol (2000) 1.22
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res (1979) 1.21
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest (1994) 1.19
Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer (2006) 1.17
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res (1987) 1.17
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res (2000) 1.16
Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine (2004) 1.15
An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther (2008) 1.15
An evaluation of the activity related to inflammation of four plants used in Thailand to treat arthritis. J Ethnopharmacol (2003) 1.14
Effects of cytotoxic agents on TdR incorporation and growth delay in human colonic tumour xenografts. Br J Cancer (1977) 1.12
Tyrosinase inhibition by extracts and constituents of Sideroxylon inerme L. stem bark, used in South Africa for skin lightening. J Ethnopharmacol (2008) 1.11
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res (1981) 1.09
The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur J Cancer Clin Oncol (1982) 1.07
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol (2001) 1.07
Ethno-veterinary medicine: screening of Nigerian medicinal plants for trypanocidal properties. J Ethnopharmacol (2001) 1.06
Antimicrobial and antiinflammatory activities of extracts and constituents of Oroxylum indicum (L.) Vent. Phytomedicine (1998) 1.05
Curcuma longa extract as a histological dye for collagen fibres and red blood cells. J Anat (2007) 1.04
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res (1997) 1.04
Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res (1999) 1.04
Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol (1999) 1.04
Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. J Nat Prod (1999) 1.03
Ethnopharmacology of some Buddleja species. J Ethnopharmacol (1984) 1.01
Immunohistochemistry of MyoD1 in adult pleomorphic soft tissue sarcomas. Am J Surg Pathol (1995) 1.01
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol (1998) 1.00
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1994) 1.00
N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res (2000) 0.98
Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells. Oncogene (2007) 0.98
Antimalarial activities of Tithonia diversifolia (Asteraceae) and Crossopteryx febrifuga (Rubiaceae) on mice in vivo. J Ethnopharmacol (2004) 0.98
Growth and characterization of childhood rhabdomyosarcomas as xenografts. J Natl Cancer Inst (1982) 0.98
Malignant rhabdoid tumor: a highly malignant childhood tumor with minimal karyotypic changes. Genes Chromosomes Cancer (1990) 0.97
An audit of laparoscopic surgeries in Ile-Ife, Nigeria. West Afr J Med (2012) 0.97
O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc Natl Acad Sci U S A (1985) 0.97
Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol (2000) 0.96
P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol (1996) 0.96
Pattern and validity of clinical diagnosis of upper gastrointestinal diseases in south-west Nigeria. Afr Health Sci (2006) 0.95
Activity of extracts and isolated naphthoquinones from Kigelia pinnata against Plasmodium falciparum. J Nat Prod (2000) 0.95
Antiplasmodial activity of extracts and alkaloids of three Alstonia species from Thailand. Planta Med (1999) 0.94
Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. Clin Cancer Res (1998) 0.94
Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol (1988) 0.94
Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer (1999) 0.93
Effects of Buddleja globosa leaf and its constituents relevant to wound healing. J Ethnopharmacol (2001) 0.93
Cytotoxic activity of indole alkaloids from Alstonia macrophylla. Planta Med (1999) 0.93
Evaluation of single-agent therapy in human colorectal tumour xenografts. Br J Cancer (1978) 0.93
Antiplasmodial activity of Cryptolepis sanguinolenta alkaloids from leaves and roots. Planta Med (2000) 0.93
Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol Biochem Behav (2003) 0.91
Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res (1996) 0.91
Pattern of death in a Nigerian teaching hospital; 3-decade analysis. Afr Health Sci (2010) 0.91
Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res (1982) 0.90
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res (1996) 0.90
Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs (1997) 0.90
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res (1998) 0.90
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother Pharmacol (2000) 0.89
Bioactive chemical constituents from Alchornea laxiflora (benth) pax and hoffman. J Ethnopharmacol (2001) 0.89
Fibroblast growth stimulation by extracts and compounds of Onosma argentatum roots. J Ethnopharmacol (2005) 0.89
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs (1996) 0.89
Resistance to rapamycin: a novel anticancer drug. Cancer Metastasis Rev (2001) 0.88
Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. Cell Growth Differ (1996) 0.88
Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res (1998) 0.88
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol (1999) 0.88
A survey from the literature of plants used to treat scorpion stings. J Ethnopharmacol (1998) 0.88
Metastatic breast cancer in a Nigerian tertiary hospital. Afr Health Sci (2011) 0.87
On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice. Cancer (1980) 0.87
Ethnobotanical survey and cytotoxicity testing of plants of South-western Nigeria used to treat cancer, with isolation of cytotoxic constituents from Cajanus cajan Millsp. leaves. J Ethnopharmacol (2010) 0.87
Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res (1994) 0.87
Effects of Khaya grandifoliola (Meliaceae) on some biochemical parameters in rats. J Ethnopharmacol (2005) 0.86
Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res (1998) 0.86
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol (1999) 0.86
Areca nut, energy metabolism and hunger in Asian men. Ann Hum Biol (2003) 0.86
Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. Biochem Pharmacol (1986) 0.86
Characteristics of thymidylate synthase purified from a human colon adenocarcinoma. Arch Biochem Biophys (1988) 0.85
Antioxidant and antimicrobial activities of Onosma argentatum and Rubia peregrina. Fitoterapia (2003) 0.85